Free Trial

Apellis Pharmaceuticals (APLS) SEC Filings & 10K Form

Apellis Pharmaceuticals logo
$30.77 +3.02 (+10.88%)
(As of 11/22/2024 ET)

Recent Apellis Pharmaceuticals SEC Filings

DateFilerForm TypeView
11/08/2024
4:31 PM
Apellis Pharmaceuticals (Subject)
BlackRock, Inc. (Filed by)
Form SC 13G
11/08/2024
9:52 AM
Apellis Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
11/05/2024
5:57 AM
Apellis Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/01/2024
5:43 PM
Apellis Pharmaceuticals (Issuer)
Francois Cedric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2024
3:15 PM
Apellis Pharmaceuticals (Issuer)
Watson David O. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2024
3:20 PM
Apellis Pharmaceuticals (Issuer)
Dunlop A. Sinclair (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2024
4:21 PM
Apellis Pharmaceuticals (Issuer)
Dunlop A. Sinclair (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2024
2:22 PM
Apellis Pharmaceuticals (Subject)
Chopas James George (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/03/2024
2:16 PM
Apellis Pharmaceuticals (Subject)
Chopas James George (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2024
3:13 PM
Apellis Pharmaceuticals (Issuer)
DeLong Mark Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2024
6:06 AM
Apellis Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
6:02 AM
Apellis Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/21/2024
6:34 PM
Apellis Pharmaceuticals (Issuer)
Dunlop A. Sinclair (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
3:50 PM
Apellis Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2024
7:09 AM
Apellis Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/09/2024
4:15 PM
Apellis Pharmaceuticals (Issuer)
Deschatelets Pascal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2024
4:13 PM
Apellis Pharmaceuticals (Subject)
Deschatelets Pascal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/07/2024
6:02 AM
Apellis Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/19/2024
6:27 PM
Apellis Pharmaceuticals (Issuer)
Sullivan Timothy Eugene (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2024
3:25 PM
Apellis Pharmaceuticals (Issuer)
Deschatelets Pascal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2024
3:17 PM
Apellis Pharmaceuticals (Subject)
Deschatelets Pascal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2024
10:24 AM
Apellis Pharmaceuticals (Subject)
Sullivan Timothy Eugene (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/20/2024
4:18 PM
Apellis Pharmaceuticals (Issuer)
Dunlop A. Sinclair (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2024
11:53 AM
Apellis Pharmaceuticals (Subject)
DeLong Mark Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/15/2024
2:22 PM
Apellis Pharmaceuticals (Subject)
Chopas James George (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2024
3:36 PM
Apellis Pharmaceuticals (Subject)
Nicholson Nur (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/08/2024
6:45 AM
Apellis Pharmaceuticals (Issuer)
Watson David O. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/01/2024
12:37 PM
Apellis Pharmaceuticals (Subject)
Sullivan Timothy Eugene (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
4:10 PM
Apellis Pharmaceuticals (Filer)
Form 10-K/A
02/27/2024
6:35 AM
Apellis Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/27/2024
6:30 AM
Apellis Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2024
6:01 AM
Apellis Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/14/2024
4:18 PM
Apellis Pharmaceuticals (Subject)
EcoR1 Capital, LLC (Filed by)
Form SC 13G/A
02/14/2024
8:23 AM
Apellis Pharmaceuticals (Subject)
Avoro Capital Advisors LLC (Filed by)
Form SC 13G/A
02/12/2024
2:19 PM
Apellis Pharmaceuticals (Subject)
Deschatelets Pascal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/12/2024
2:22 PM
Apellis Pharmaceuticals (Subject)
Sullivan Timothy Eugene (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/12/2024
2:27 PM
Apellis Pharmaceuticals (Subject)
DeLong Mark Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/12/2024
2:28 PM
Apellis Pharmaceuticals (Subject)
Townsend Adam J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/12/2024
2:43 PM
Apellis Pharmaceuticals (Subject)
Watson David O. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/12/2024
2:46 PM
Apellis Pharmaceuticals (Subject)
Francois Cedric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/31/2024
3:34 PM
Apellis Pharmaceuticals (Issuer)
Sullivan Timothy Eugene (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Urgent: Monday is the last day to start collecting up to $4,243 in monthly dividends (Ad)

You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. Registration to collect your first payout closes this week, so you are advised to sign up today.

Click here to find out more and get started.
01/31/2024
3:36 PM
Apellis Pharmaceuticals (Issuer)
Townsend Adam J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:38 PM
Apellis Pharmaceuticals (Issuer)
Watson David O. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:23 PM
Apellis Pharmaceuticals (Issuer)
Eisele Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:26 PM
Apellis Pharmaceuticals (Issuer)
Francois Cedric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:28 PM
Apellis Pharmaceuticals (Issuer)
Lewis Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
3:31 PM
Apellis Pharmaceuticals (Issuer)
Nicholson Nur (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2024
9:50 AM
Apellis Pharmaceuticals (Subject)
Eisele Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/30/2024
9:04 AM
Apellis Pharmaceuticals (Subject)
Lewis Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
2:15 PM
Apellis Pharmaceuticals (Subject)
Deschatelets Pascal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
2:15 PM
Apellis Pharmaceuticals (Subject)
Townsend Adam J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
2:16 PM
Apellis Pharmaceuticals (Subject)
DeLong Mark Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
2:16 PM
Apellis Pharmaceuticals (Subject)
Nicholson Nur (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
2:17 PM
Apellis Pharmaceuticals (Subject)
Lewis Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2024
2:19 PM
Apellis Pharmaceuticals (Subject)
Francois Cedric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2024
6:28 PM
Apellis Pharmaceuticals (Issuer)
Francois Cedric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:13 PM
Apellis Pharmaceuticals (Issuer)
Sullivan Timothy Eugene (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:15 PM
Apellis Pharmaceuticals (Issuer)
Townsend Adam J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:17 PM
Apellis Pharmaceuticals (Issuer)
Watson David O. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:00 PM
Apellis Pharmaceuticals (Issuer)
Chopas James George (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:01 PM
Apellis Pharmaceuticals (Issuer)
DeLong Mark Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:03 PM
Apellis Pharmaceuticals (Issuer)
Deschatelets Pascal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:05 PM
Apellis Pharmaceuticals (Issuer)
Eisele Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:07 PM
Apellis Pharmaceuticals (Issuer)
Lewis Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
5:11 PM
Apellis Pharmaceuticals (Issuer)
Nicholson Nur (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
11:36 AM
Apellis Pharmaceuticals (Subject)
Eisele Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2024
9:21 AM
Apellis Pharmaceuticals (Subject)
Lewis Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:33 PM
Apellis Pharmaceuticals (Subject)
Deschatelets Pascal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:34 PM
Apellis Pharmaceuticals (Subject)
Lewis Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:14 PM
Apellis Pharmaceuticals (Subject)
Townsend Adam J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:18 PM
Apellis Pharmaceuticals (Subject)
Chopas James George (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:18 PM
Apellis Pharmaceuticals (Subject)
Francois Cedric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:19 PM
Apellis Pharmaceuticals (Subject)
Watson David O. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:21 PM
Apellis Pharmaceuticals (Subject)
DeLong Mark Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:21 PM
Apellis Pharmaceuticals (Subject)
Sullivan Timothy Eugene (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:21 PM
Apellis Pharmaceuticals (Subject)
Nicholson Nur (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
2:23 PM
Apellis Pharmaceuticals (Subject)
Eisele Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
7:00 AM
Apellis Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/18/2024
3:54 PM
Apellis Pharmaceuticals (Issuer)
Lewis Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/18/2024
3:55 PM
Apellis Pharmaceuticals (Issuer)
Eisele Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:47 PM
Apellis Pharmaceuticals (Issuer)
Deschatelets Pascal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:37 PM
Apellis Pharmaceuticals (Issuer)
Townsend Adam J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:38 PM
Apellis Pharmaceuticals (Issuer)
Watson David O. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:40 PM
Apellis Pharmaceuticals (Issuer)
Nicholson Nur (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:41 PM
Apellis Pharmaceuticals (Issuer)
DeLong Mark Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:43 PM
Apellis Pharmaceuticals (Issuer)
Lewis Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:45 PM
Apellis Pharmaceuticals (Issuer)
Chopas James George (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:32 PM
Apellis Pharmaceuticals (Issuer)
Francois Cedric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:33 PM
Apellis Pharmaceuticals (Issuer)
Baumal Caroline (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:36 PM
Apellis Pharmaceuticals (Issuer)
Sullivan Timothy Eugene (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
11:24 AM
Apellis Pharmaceuticals (Issuer)
Eisele Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Urgent: Monday is the last day to start collecting up to $4,243 in monthly dividends (Ad)

You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. Registration to collect your first payout closes this week, so you are advised to sign up today.

Click here to find out more and get started.
01/17/2024
9:46 AM
Apellis Pharmaceuticals (Subject)
Eisele Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2024
9:18 AM
Apellis Pharmaceuticals (Subject)
Lewis Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:48 PM
Apellis Pharmaceuticals (Subject)
Eisele Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:49 PM
Apellis Pharmaceuticals (Subject)
Francois Cedric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:50 PM
Apellis Pharmaceuticals (Subject)
Chopas James George (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:51 PM
Apellis Pharmaceuticals (Subject)
Lewis Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:53 PM
Apellis Pharmaceuticals (Subject)
Deschatelets Pascal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:41 PM
Apellis Pharmaceuticals (Subject)
Sullivan Timothy Eugene (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
2:44 PM
Apellis Pharmaceuticals (Subject)
Watson David O. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:APLS) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners